FY2025 · ended Dec 31, 2025 · Revenue $30.25M, -46.5% YoY · Filed Apr 10, 2026
Scilex Holding Company (SCLX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $30.3 million and a net loss of $374.1 million. Free cash flow was $3.7 million. As of Jun 30, 2026 it held $581,000 in cash and investments and $14.8 million in total debt.
Revenue (TTM)
$31.61M
-28.5% vs year-ago TTM
Net income (TTM)
$-464.56M
-473.7% vs year-ago TTM
Operating cash flow (TTM)
$-17.09M
-182.5% vs year-ago TTM
Free cash flow
$3.68M
-81.0% vs prior year
EPS (TTM)
$194.28
+1005.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
8.49M
-96.5% vs prior year
Net cash
$-14.17M
as of Jun 30, 2026
Operating margin
-1136.4%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SCLX (Nasdaq), SCLXW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Palo Alto, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1820190
- Former names
- Scilex Holding Company/DE (until Nov 30, 2022); Vickers Vantage Corp. I (until Nov 15, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $30.3M | $56.6M | $46.7M | $38.0M | — |
| Operating income | -$346.0M | -$83.4M | -$105.4M | -$50.6M | -$35.8M |
| Net income | -$374.1M | -$72.8M | -$114.3M | -$23.4M | -$88.4M |
| Diluted EPS | -$36.48 | -$8.05 | -$1.28 | -$0.17 | -$0.67 |
| Operating cash flow | $3.8M | $19.3M | -$20.7M | -$21.3M | -$28.7M |
| Free cash flow | $3.7M | $19.3M | -$20.7M | -$21.3M | — |
| Total assets | $365.0M | $93.0M | $101.3M | $86.5M | $77.9M |
| Total liabilities | $576.7M | $285.6M | $274.2M | $50.3M | $301.8M |
| Stockholders' equity | -$207.8M | -$192.6M | -$172.9M | $36.2M | -$223.9M |
| Cash and investments | $11.0M | $3.3M | $3.9M | $2.2M | $4.6M |
| Total debt | $14.9M | $2.2M | $3.0M | $1.4M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 29, 2026 | Sep 25, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 12, 2026 | Aug 8, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets
|
Jul 22, 2026 | Jul 18, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jul 6, 2026 | Jul 3, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jun 29, 2026 | Jun 24, 2026 |
All 742 Scilex Holding Company SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.